Patent SG-11201901271V-A (SG)
Title: Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
Inventor: HADDEN JOHN
IPC: C07K16/28
Filed: 2017-08-18
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 1111111111011111010011111101111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2018/035395 Al 22 February 2018 (22.02.2018) WIP0 I PCT — (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: (74) Agent: GATES, Edward, R. et al.; Wolf, Greenfield & A61K 38/19 (2006.01) A61K 39/395 (2006.01) Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 A61K 38/20 (2006.01) CO7K 16/28 (2006.01) (US). International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2017/047477 kind of national protection available): AE, AG, AL, AM, International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 18 August 2017 (18.08.2017) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/377,051 19 August 2016 (19.08.2016) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Applicant: IRX THERAPEUTICS, INC. [US/US]; 654 Madison Avenue, Suite 1601, New York, NY 10065 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, Inventors: HADDEN, John, W.; 25 East 86th St, New GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, York, NY 10028 (US). BERINSTEIN, Neil, L.; 2075 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Bayview Avenue, Toronto, ON M4N 3M5 (CA). EGAN, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, James, E.; 2 Cedar Hill Road, Stony Brook, NY 11790 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (US). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = = the CTLA-4 Title: USES OF PD-1/PD-L1 INHIBITORS AND/OR CTLA-4 INHIBITORS WITH A BIOLOGIC CONTAINING MULTIPLE COMPONENTS TO TREAT CANCER Difference in Mean Membrane Intensity of PD-L1 Expression After Treatment CYTOKINE -L1) of = (54) = = = = 1.2 a) _ at 1 18 0.8 ,_.4 0.6 ,...., &, -' 0.4 -,- ct r.:1 . = = _ = = — -derived programmed (1.) 0 0 ct -0.2 U -0.4 FIG. 2 : Aspects of the disclosure relate to methods for treating cancer, e.g., by administering to a subject having cancer a primary biologic with multiple cytokine components in combination with an antagonist of programmed cell death-ligand 1 (PD cell death 1 (PD-1) and/or with an antagonist of cytotoxic T-lymphocyte- associated protein 4 (CTLA-4). Other aspects disclosure relate to methods of identifying a subject for treatment with an antagonist of PD-L1 or PD-1 and/or an antagonist or assessing the likelihood that a subject will be responsive to an antagonist of PD-Ll or PD-1 and/or an antagonist of CTLA-4. = _ 1-1 kin tz . M in (57) en cell --.., © or GC of C 1-1 ei O [Continued on next page] WO 2018/035395 Al MIDEDIMOMMIDIREIHRIMIOMEHINIMEMOVOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))